Page 117 - 2021_06-Haematologica-web

Bile acids reduce GvHD and preserve the GvL effect
(CoNfirm, FKZ 01ZX1708F) and within the Medical Informatics Funding Scheme (MIRACUM, FKZ 01ZZ1606A-H). BG receives support through the Deutsche Forschungsgemeinschaft (DFG) SFB1160/2_B5, under Germany's Excellence Strategy (CIBSS – EXC-2189 – Project ID 390939984, and RESIST –
EXC 2155 – Project ID 39087428); through the E-rare program of the EU, managed by the DFG, grant code GR1617/14- 1/iPAD; and through the „Netzwerke Seltener Erkrankungen“ of the German Ministry of Education and Research (BMBF), grant code: GAIN_01GM1910A.
References
1. de Lima M, Porter DL, Battiwalla M, et al. Proceedings from the National Cancer Institute's Second International Workshop on the biology, prevention, and treatment of relapse after hematopoietic stem cell transplantation: part III. Prevention and treatment of relapse after allogeneic trans- plantation. Biol Blood Marrow Transplant. 2014;20(1):4-13.
2. Zeiser R, Blazar BR. Acute Graft-versus- Host Disease - Biologic Process, Prevention, and Therapy. N Engl J Med. 2017; 377(22):2167-2179.
3. McDonald GB. How I treat acute graft-ver- sus-host disease of the gastrointestinal tract and the liver. Blood. 2016;127(12):1544- 1550.
4. Takashima S, Kadowaki M, Aoyama K, et al. The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by pro- tecting intestinal stem cells. J Exp Med. 2011;208(2):285-294.
5.Eriguchi Y, Takashima S, Oka H, et al. Graft-versus-host disease disrupts intestin- al microbial ecology by inhibiting Paneth cell production of alpha-defensins. Blood. 2012;120(1):223-231.
6.Eriguchi Y, Nakamura K, Yokoi Y, et al. Essential role of IFN-gamma in T cell-asso- ciated intestinal inflammation. JCI Insight. 2018;3(18):e121886.
7. Takashima S, Martin ML, Jansen SA, et al. T cell-derived interferon-gamma programs stem cell death in immune-mediated intes- tinal damage. Sci Immunol. 2019;4 (42):eaay8556.
8.Monte MJ, Marin JJ, Antelo A, Vazquez- Tato J. Bile acids: chemistry, physiology, and pathophysiology. World J Gastroenterol. 2009;15(7):804-816.
9. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003;72:137-174.
10. Benz C, Angermuller S, Tox U, et al. Effect of tauroursodeoxycholic acid on bile-acid- induced apoptosis and cytolysis in rat hepatocytes. J Hepatol. 1998;28(1):99-106.
11.Sola S, Aranha MM, Steer CJ, Rodrigues CM. Game and players: mitochondrial apoptosis and the therapeutic potential of ursodeoxycholic acid. Curr Issues Mol Biol. 2007;9(2):123-138.
12. Colell A, Coll O, Garcia-Ruiz C, et al. Tauroursodeoxycholic acid protects hepa- tocytes from ethanol-fed rats against tumor necrosis factor-induced cell death by replenishing mitochondrial glutathione. Hepatology. 2001;34(5):964-971.
13. Castro RE, Sola S, Ramalho RM, Steer CJ, Rodrigues CM. The bile acid taurour- sodeoxycholic acid modulates phosphory- lation and translocation of bad via phos- phatidylinositol 3-kinase in glutamate- induced apoptosis of rat cortical neurons. J Pharmacol Exp Ther. 2004;311(2):845-852.
14. Ishigami F, Naka S, Takeshita K, Kurumi Y, Hanasawa K, Tani T. Bile salt taurour- sodeoxycholic acid modulation of Bax translocation to mitochondria protects the liver from warm ischemia-reperfusion
injury in the rat. Transplantation. 2001;72
(11):1803-1807.
15. Vavassori P, Mencarelli A, Renga B,
Distrutti E, Fiorucci S. The bile acid recep- tor FXR is a modulator of intestinal innate immunity. J Immunol. 2009;183(10):6251- 6261.
16. Joshi NM, Hassan S, Jasani P, et al. Bile acid malabsorption in patients with graft-ver- sus-host disease of the gastrointestinal tract. Br J Haematol. 2012;157(3):403-407.
17. Michonneau D, Latis E, Curis E, et al. Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites. Nat Commun. 2019;10(1):5695.
18. Sato T, Clevers H. Primary mouse small intestinal epithelial cell cultures. Methods Mol Biol. 2013;945:319-328.
19. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006;47(2):241-259.
20. Camilleri M. Bile Acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver. 2015;9(3):332-339.
Swann JR, Want EJ, Geier FM, et al. Systemic gut microbial modulation of bile acid metabolism in host tissue compart- ments. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4523-4530.
22. Jenq RR, Ubeda C, Taur Y, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow trans- plantation. J Exp Med. 2012;209(5):903- 911.
23. Holler E, Butzhammer P, Schmid K, et al. Metagenomic analysis of the stool micro- biome in patients receiving allogeneic stem cell transplantation: loss of diversity is asso- ciated with use of systemic antibiotics and more pronounced in gastrointestinal graft- versus-host disease. Biol Blood Marrow Transplantat. 2014;20(5):640-645.
24. Staffas A, Burgos da Silva M, van den Brink MR. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-ver- sus-host disease. Blood. 2017;129(8):927- 933.
25. Zeiser R, Vago L. Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. Blood. 2019;133(12):1290- 1297.
26. Amaral JD, Viana RJ, Ramalho RM, Steer CJ, Rodrigues CM. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res. 2009;50(9):1721-1734.
27. Rodrigues CM, Fan G, Wong PY, Kren BT, Steer CJ. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species pro- duction. Mol Med. 1998;4(3):165-178.
28. Faubion WA, Guicciardi ME, Miyoshi H, et al. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest. 1999;103(1):137-145.
29. Yerushalmi B, Dahl R, Devereaux MW, Gumpricht E, Sokol RJ. Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochon- drial permeability transition. Hepatology. 2001;33(3):616-626.
30. Rust C, Karnitz LM, Paya CV, Moscat J, Simari RD, Gores GJ. The bile acid tau- rochenodeoxycholate activates a phos- phatidylinositol 3-kinase-dependent sur- vival signaling cascade. J Biol Chem. 2000; 275(26):20210-20216.
31. Torchia EC, Stolz A, Agellon LB. Differential modulation of cellular death and survival pathways by conjugated bile acids. BMC Biochem. 2001;2:11.
32. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest. 1998;101(12):2790-2799.
33. Rodrigues CM, Ma X, Linehan-Stieers C, Fan G, Kren BT, Steer CJ. Ursodeoxycholic acid prevents cytochrome c release in apop- tosis by inhibiting mitochondrial mem- brane depolarization and channel forma- tion. Cell Death Differ. 1999;6(9):842-854.
34. Schoemaker MH, Conde de la Rosa L, Buist-Homan M, et al. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apopto- sis via activation of survival pathways. Hepatology. 2004;39(6):1563-1573.
35. Im E, Martinez JD. Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells. J Nutr. 2004;134(2):483- 486.
36. Vandewynckel YP, Laukens D, Devisscher L, et al. Tauroursodeoxycholic acid damp- ens oncogenic apoptosis induced by endo- plasmic reticulum stress during hepatocar- cinogen exposure. Oncotarget. 2015; 6(29):28011-28025.
37. PengP,MaQ,WangL,etal. Preconditioning with tauroursodeoxycholic acid protects against contrast-induced HK-2 cell apoptosis by inhibiting endoplasmic reticulum stress. Angiology. 2015; 66(10): 941-949.
38. Ruutu T, Juvonen E, Remberger M, et al. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. Biol Blood Marrow Transplant. 2014;20(1):135-138.
39. Essell JH, Thompson JM, Harman GS, et al. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone mar- row transplant patients. Bone Marrow Transplant. 1992;10(4):367-372.
40. Thornley I, Lehmann LE, Sung L, et al. A multiagent strategy to decrease regimen- related toxicity in children undergoing allo- geneic hematopoietic stem cell transplanta- tion. Biol Blood Marrow Transplant. 2004; 10(9):635-644.
41. Tay J, Tinmouth A, Fergusson D, Huebsch L, Allan DS. Systematic review of con- trolled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007; 13(2):206-217.
42. Koyama M, Mukhopadhyay P, Schuster IS,
21.
haematologica | 2021; 106(8)
2145